Siam Pharmaceutical
Siam Pharmaceutical is one of Thailand's oldest and largest private pharmaceutical manufacturers, founded 1939 and family-controlled. Domestic-focused generics, OTC, specialty-formulation manufacturing. Distribution channels: hospital, clinic direct supply, retail pharmacy, wholesaler network. Not listed on SET; private-company filings via DBD (Department of Business Development). Competitive niche: mid-to-large scale Thai-domestic generics producer competing with GPO, listed peers, ~500 smaller private manufacturers.
Snapshot
Headline numbers a buyer checks first.
Estimated revenue
THB 3-5B
FY2024 estimate
Private company; DBD filing-based industry estimate
Founded
1939
Historical
85+ year operating history; family-controlled
Product portfolio
500+ SKUs (generics, OTC, specialty)
FY2024
Channels
Hospital, retail pharmacy, wholesale
FY2024
Manufacturing
GMP-certified plants, Thailand
FY2024
Regulatory
Thai FDA registered; PIC/S GMP pathway
FY2024
What this company actually does
Siam Pharmaceutical manufactures, distributes generic prescription drugs, OTC products, and specialty formulations to Thai domestic hospitals, retail pharmacies, and wholesalers. Product portfolio covers common therapeutic categories — cardiovascular, antibiotic, analgesic, respiratory, gastrointestinal. 85+ year operating history provides deep hospital-formulary, pharmacy-channel relationships. GMP-compliant manufacturing plants in Thailand; Thai FDA registered.[]
Strategic position: Siam Pharmaceutical is a leading private Thai domestic generics manufacturer. Not listed limits transparency but DBD filings, industry sources confirm scale is among largest private producers. Competitive pressure: GPO, listed MEGA, TNP at larger scale, ~500 smaller private manufacturers on price, imported generics on cost. Defensibility: long-standing channel relationships, GMP track record, product-portfolio breadth.[]
Competitive position snapshot
Where Siam Pharmaceutical sits in the Thai pharma landscape.
Scale
Mid-to-large private manufacturer
Industry estimates place Siam Pharmaceutical among Thailand's top 5 private pharmaceutical manufacturers by revenue. With 85+ years in market, the company holds formulary positions in 300-400 public hospitals nationwide — a distribution depth that newer entrants cannot replicate quickly.[]
Product breadth
500+ SKU generics and OTC portfolio
Portfolio covers cardiovascular (statins, antihypertensives), antibiotics, analgesics, gastrointestinals, respiratory, dermatologicals. OTC brands include established community-pharmacy staples recognised by Thai retail pharmacists — channel-relationship assets that translate into preferred-vendor status vs smaller private competitors.[]
Manufacturing
GMP plants, Thai FDA registered
Multiple manufacturing facilities in Thailand certified to Thai GMP and on the PIC/S harmonisation pathway. GMP compliance is the minimum bar for hospital-tender eligibility. Siam's 85-year track record means decades of accumulated audit-compliance cycles across MoPH and NLEM tender rounds.[]
Governance
Family-controlled; DBD filings the only window
Private status limits financial transparency. DBD (Department of Business Development) annual filings provide revenue, profit, asset snapshots but with a 12-18 month lag. Family-controlled management means strategic pivots (e.g. biosimilar entry, export expansion) are opaque without management commentary.[]
Thai generic pharma landscape: peer scale comparison
Siam Pharmaceutical sits between the GPO and smaller private competitors by scale.
GPO (Govt Pharmaceutical Org)
Listed?
State-owned
Revenue (approx)
$0.29-12B
Focus
Generics, essential medicines, ARV
Mega Lifesciences (SET: MEGA)
Listed?
Yes
Revenue (approx)
$0.203-8B
Focus
OTC brands, ASEAN distribution
Listed?
No (private)
Revenue (approx)
$0.087-5B est.
Focus
Generics, OTC, hospital direct
Thai Nakorn Patana (SET: TNP)
~500 smaller privates
Listed?
No
Revenue (approx)
$0.003-1B each
Focus
Narrow generics, regional
| Company | Listed? | Revenue (approx) | Focus |
|---|---|---|---|
| GPO (Govt Pharmaceutical Org) | State-owned | $0.29-12B | Generics, essential medicines, ARV |
| Mega Lifesciences (SET: MEGA) | Yes | $0.203-8B | OTC brands, ASEAN distribution |
| Siam Pharmaceutical | No (private) | $0.087-5B est. | Generics, OTC, hospital direct |
| Thai Nakorn Patana (SET: TNP) | Yes | ~ $87M | Generics, OTC, hospital domestic |
| ~500 smaller privates | No | $0.003-1B each | Narrow generics, regional |
Hospital-formulary depth is the core defensibility
Thailand's public hospital procurement is governed by the National List of Essential Medicines (NLEM), administered through MoPH's Drug and Medical Supply Information Center. Suppliers to UCS (Universal Coverage Scheme) hospitals must be NLEM-listed and GMP-certified. Siam Pharmaceutical's 85-year hospital-supply track record and GMP credentials place it among the preferred domestic suppliers for public-hospital tender rounds — a competitive position that newer or smaller manufacturers cannot match without years of compliance build-up.[]
Independent and chain retail pharmacies (Boots Thailand, Watsons, Fascino, independent operators) are the second channel. Siam Pharmaceutical's OTC portfolio presence at retail has brand-recognition value in a market where pharmacist recommendation heavily influences OTC switching decisions. This channel provides a revenue stream insulated from hospital-procurement pricing pressure.
Competitive position snapshot
Where Siam Pharmaceutical sits in the Thai pharma landscape.
Scale
Mid-to-large private manufacturer
Industry estimates place Siam Pharmaceutical among Thailand's top 5 private pharmaceutical manufacturers by revenue. With 85+ years in market, the company holds formulary positions in 300-400 public hospitals nationwide — a distribution depth that newer entrants cannot replicate quickly.[]
Product breadth
500+ SKU generics and OTC portfolio
Portfolio covers cardiovascular (statins, antihypertensives), antibiotics, analgesics, gastrointestinals, respiratory, dermatologicals. OTC brands include established community-pharmacy staples recognised by Thai retail pharmacists — channel-relationship assets that translate into preferred-vendor status vs smaller private competitors.[]
Manufacturing
GMP plants, Thai FDA registered
Multiple manufacturing facilities in Thailand certified to Thai GMP and on the PIC/S harmonisation pathway. GMP compliance is the minimum bar for hospital-tender eligibility. Siam's 85-year track record means decades of accumulated audit-compliance cycles across MoPH and NLEM tender rounds.[]
Governance
Family-controlled; DBD filings the only window
Private status limits financial transparency. DBD (Department of Business Development) annual filings provide revenue, profit, asset snapshots but with a 12-18 month lag. Family-controlled management means strategic pivots (e.g. biosimilar entry, export expansion) are opaque without management commentary.[]
Thai generic pharma landscape: peer scale comparison
Siam Pharmaceutical sits between the GPO and smaller private competitors by scale.
GPO (Govt Pharmaceutical Org)
Listed?
State-owned
Revenue (approx)
$0.29-12B
Focus
Generics, essential medicines, ARV
Mega Lifesciences (SET: MEGA)
Listed?
Yes
Revenue (approx)
$0.203-8B
Focus
OTC brands, ASEAN distribution
Listed?
No (private)
Revenue (approx)
$0.087-5B est.
Focus
Generics, OTC, hospital direct
Thai Nakorn Patana (SET: TNP)
~500 smaller privates
Listed?
No
Revenue (approx)
$0.003-1B each
Focus
Narrow generics, regional
| Company | Listed? | Revenue (approx) | Focus |
|---|---|---|---|
| GPO (Govt Pharmaceutical Org) | State-owned | $0.29-12B | Generics, essential medicines, ARV |
| Mega Lifesciences (SET: MEGA) | Yes | $0.203-8B | OTC brands, ASEAN distribution |
| Siam Pharmaceutical | No (private) | $0.087-5B est. | Generics, OTC, hospital direct |
| Thai Nakorn Patana (SET: TNP) | Yes | ~ $87M | Generics, OTC, hospital domestic |
| ~500 smaller privates | No | $0.003-1B each | Narrow generics, regional |
Hospital-formulary depth is the core defensibility
Thailand's public hospital procurement is governed by the National List of Essential Medicines (NLEM), administered through MoPH's Drug and Medical Supply Information Center. Suppliers to UCS (Universal Coverage Scheme) hospitals must be NLEM-listed and GMP-certified. Siam Pharmaceutical's 85-year hospital-supply track record and GMP credentials place it among the preferred domestic suppliers for public-hospital tender rounds — a competitive position that newer or smaller manufacturers cannot match without years of compliance build-up.[]
Independent and chain retail pharmacies (Boots Thailand, Watsons, Fascino, independent operators) are the second channel. Siam Pharmaceutical's OTC portfolio presence at retail has brand-recognition value in a market where pharmacist recommendation heavily influences OTC switching decisions. This channel provides a revenue stream insulated from hospital-procurement pricing pressure.
Watchpoints
Hospital-formulary position
Long-standing relationships vs GPO, listed, foreign-generic challenge.
Retail-pharmacy depth
Channel, brand strength in independent, chain retail pharmacies.
Biosimilar, specialty pivot
Capability expansion beyond generics, OTC; uncertain given private status.
Family-succession governance
Family-controlled company; succession planning, strategic direction uncertainty.
Related Market profiles
Peers, parents, partners, agencies, and other Pharmaceuticals actors.
Competitor
Government Pharmaceutical Organisation (GPO)
State generics manufacturer; overlapping product categories.
Open Market profile →
Competitor
Mega Lifesciences
Largest listed pharma; different business model (distribution vs manufacturing).
Open Market profile →
Competitor
Thai Nakorn Patana
Listed generics, OTC peer at smaller scale.
Open Market profile →
Sector peer
Government Pharmaceutical Organization (GPO)
Thai state pharmaceutical manufacturer; produces essential medicines, vaccines, and APIs under MoPH mandate for public-health security.
Open Market profile →
Sources + data provenance
Every filing, filing-adjacent register, or trusted industry source cited in this profile.
Siam Pharmaceutical Corporation — Company Disclosures (private)
| Source | Publisher | Grade | As of |
|---|---|---|---|
| Siam Pharmaceutical Corporation — Company Disclosures (private) | Siam Pharmaceutical Corporation | Supporting | 2025-12-31 |
Reports featuring this profile
Thailand Pharmaceutical Manufacturing Market Intelligence
Private generic-Rx and OTC manufacturer; NHSO formulary supplier
Open report →
Sits alongside 4 other Atlas profilesThailand Pharmaceuticals Market Intelligence
Leading private Thai generics, OTC manufacturer since 1939.
Open report →
Sits alongside 7 other Atlas profilesThailand Luxury & Premium Goods Market Intelligence
Siam Pharmaceutical luxury beauty, fragrance distribution, premium wellness retail.
Open report →
Sits alongside 3 other Atlas profilesThailand Jewelry & Precious Metals Market Intelligence
Siam Pharmaceutical premium retail channels adjacent to luxury, jewellery.
Open report →
Sits alongside 3 other Atlas profilesThailand Pharma Generic vs Branded Deep Dive
Siam Pharmaceutical (SET: SPC) listed Thai generic leader.
Open report →
Sits alongside 7 other Atlas profilesRelated Market profiles
competitor
Government Pharmaceutical Organisation (GPO)
Thai state pharmaceutical manufacturer; generics, HIV ARV, biosimilar, Strategic Stockpile; FY2024 revenue ~THB 16B.
competitor
Mega Lifesciences
Largest Thai-listed pharma by revenue; emerging-market distribution franchise; FY2024 revenue ~THB 16B.
competitor
Thai Nakorn Patana
Listed Thai generics, OTC, hospital products; FY2024 revenue ~THB 3B; domestic focus.